{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:46:54Z","timestamp":1760204814950},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T00:00:00Z","timestamp":1440633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Multiple guidelines exist for the use of live viral vaccines for measles\u2010mumps\u2010rubella (<jats:styled-content style=\"fixed-case\">MMR<\/jats:styled-content>), varicella and yellow fever in people with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> infections, but these guidelines do not make recommendations regarding live attenuated herpes zoster vaccine (<jats:styled-content style=\"fixed-case\">LAHZV<\/jats:styled-content>), which is approved for people over 50\u00a0years in the general population. <jats:styled-content style=\"fixed-case\">LAHZV<\/jats:styled-content> is made with the same virus used in varicella vaccine. The incidence of herpes zoster remains increased in people with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> infection, even when on suppressive antiretroviral therapy, and a growing proportion of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected patients are over 50\u00a0years of age. The purpose of this article is to review the use of varicella vaccine and <jats:styled-content style=\"fixed-case\">LAHZV<\/jats:styled-content> in people with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> infection and to make recommendations about the use of <jats:styled-content style=\"fixed-case\">LAHZV<\/jats:styled-content> in adults with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A PubMed search was undertaken using the terms \u2018herpes zoster <jats:styled-content style=\"fixed-case\">AND HIV<\/jats:styled-content>\u2019 and \u2018varicella <jats:styled-content style=\"fixed-case\">AND HIV<\/jats:styled-content>\u2019. Reference lists were also reviewed for pertinent citations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Varicella vaccine is recommended in varicella\u2010susceptible adults, as long as they have a <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 count &gt;\u00a0200\u00a0cells\/\u03bcL, the same <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 threshold used for <jats:styled-content style=\"fixed-case\">MMR<\/jats:styled-content> and yellow fever vaccines. No transmission of vaccine strain <jats:italic>Varicella zoster<\/jats:italic> virus has been documented in people with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> infections with a <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 count above this threshold. <jats:styled-content style=\"fixed-case\">LAHZV<\/jats:styled-content> was administered to 295 <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected adults with a <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 count &gt;\u00a0200\u00a0cells\/\u03bcL, and was safe and immunogenic with no cases of vaccine strain infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>It is recommended that <jats:styled-content style=\"fixed-case\">LAHZV<\/jats:styled-content> be administered to <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected adults with a <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 count above 200\u00a0cells\/\u03bcL, the same <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 threshold used for other live attenuated viral vaccines.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12311","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T01:36:06Z","timestamp":1440725766000},"page":"305-310","source":"Crossref","is-referenced-by-count":17,"title":["Live attenuated herpes zoster vaccine for <scp>HIV<\/scp>\u2010infected adults"],"prefix":"10.1111","volume":"17","author":[{"given":"SD","family":"Shafran","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Department of Medicine University of Alberta Edmonton AB Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1302674"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00916011"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318266cd3c"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-372"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-10-34"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit165"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu1161"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir970"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu058"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61113-7"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283324283"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir626"},{"key":"e_1_2_6_15_1","unstructured":"Centers for Disease Control and Prevention.HIV Surveillance Report 2011; 23. Available athttp:\/\/www.cdc.gov\/hiv\/surveillance\/resources\/reports\/2011report\/index.htm(accessed 16 February 2015)."},{"key":"e_1_2_6_16_1","unstructured":"Panel on Opportunistic Infections in HIV\u2010Infected Adults and Adolescents.Guidelines for the prevention and treatment of opportunistic infections in HIV\u2010infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention the National Institutes of Health and the HIV Medicine Association of the Infectious Diseases Society of America. Available athttp:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf(accessed 16 February 2015)."},{"key":"e_1_2_6_17_1","unstructured":"European AIDS Clinical Society. Available athttp:\/\/eacs.sanfordguide.com\/prevention-non-infectious-co-morbidities\/vaccination(last modified 11 October 2013) (accessed 16 February 2015)."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.10.027"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.Supplement_3.S320"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu970"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/514147"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.115972"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/505149"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/652798"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit684"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.4.10654"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001420"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7304"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3497"},{"key":"e_1_2_6_30_1","unstructured":"BensonCA HuaL AndersenJet\u00a0al.ZOSTAVAX is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2 randomized double\u2010blind placebo\u2010controlled trial.19th\u00a0Conference on Retroviruses and Opportunistic\u00a0Infections.Seattle WA 5\u20138 March 2012 [Abstract 96]."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit344"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit365"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu606"},{"key":"e_1_2_6_34_1","first-page":"603","article-title":"Measles pneumonitis following measles\u2010mumps\u2010rubella vaccination of a patient with HIV infection, 1993","volume":"45","author":"Centers for Disease Control and Prevention","year":"1996","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"e_1_2_6_35_1","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples JE","year":"2010","journal-title":"MMWR Recomm Rep"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12311","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:05:09Z","timestamp":1696331109000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,27]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/hiv.12311"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12311","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,27]]}}}